<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Hypokalaemia, hyperkalaemia, hypomagnesaemia MeG-CLS-073</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
<script src="myScript.js"></script><link rel="stylesheet" href="myStyle.css"></head>
<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script>
<article class="markdown-body">
<h1 id="hypokalaemia-hyperkalaemia-and-hypomagnesaemia">Hypokalaemia, hyperkalaemia and hypomagnesaemia</h1>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<p>Abnormalities in serum potassium are relatively common in our admitted population, but can also be seen in outpatients. Abnormal K is a risk factor for sudden cardiac death and must be addressed whenever it is noted. Abnormal magnesium levels are less common and do not need to be actively sought out except in the presence of hypokalaemia, which will be difficult to correct in the presence of hypomagnesaemia.</p>
<p>Falsely high potassium levels are very common, usually resulting from errors in taking blood samples and handling the sample prior to analysis. Abnormal potassium levels must always be rechecked prior to treatment – although where the initial result is severe and consistent with the clinical state of the patient, treatment may be initiated prior to receiving the repeated result.</p>
<h2 id="target-users">Target users</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nurses</p>
</div></li>
</ul>
<h2 id="target-area-of-use">Target area of use </h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Outpatient department</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ward</p>
</div></li>
</ul>
<h2 id="key-areas-of-focus-new-additions-changes">Key areas of focus / New additions / Changes </h2>
<p>This guidelines addresses the correction of abnormal potassium and magnesium results.</p>
<p>Note that great care should be taken in correcting low potassium and magnesium levels in malnourished children as the supplements they are given already contain extra doses of these minerals. Senior support should be sought where the measured level is very low.</p>
<h2 id="limitations">Limitations</h2>
<p>Patients requiring dialysis must be referred to the teaching hospital.</p>
<h1 id="hypokalaemia">Hypokalaemia</h1>
<p>This defined as K &lt; 3.5 mmol/l. Mild to moderate level is between 2.5 mmol/L and 3.4 mmol/L and severe hypokalaemia is defined as &lt; 2.5 mmol/L</p>
<h2 id="causes">Causes</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Enteral losses e.g. diarrhoea , vomiting</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Drugs e.g. insulin, theophylline, caffeine, salbutamol, loop and thiazide diuretics</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Metabolic alkalosis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Malnutrition with refeeding</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hypomagnesemia (it will be impossible to correct the hypokalaemia until the Mg level is treated)</p>
</div></li>
</ul>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs </h2>
<p>Patients are usually asymptomatic.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Weakness</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Respiratory compromise</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Paralysis.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>ECG changes: T wave depression and inversion, ST Segment depression, U waves, cardiac depression</p>
</div></li>
</ul>
<h2 id="management">Management </h2>
<p>Always repeat the electrolytes to ensure the initial result is accurate. For severe hypokalaemia, start treatment before this result is available, but it must be reviewed immediately the repeat result is available.</p>
<p>Check serum magnesium and bicarbonate.</p>
<p>Withdraw medications that cause hypokalaemia.</p>
<p>Dietary supplementation with potassium – food for patients with mild hypokalaemia e.g bananas, oranges, green leafy vegetables, potatoes, cucumbers etc.</p>
<p>Note that F75 and F100 have extra potassium in them, so malnourished children with mild to moderate hypokalaemia do not need extra oral potassium supplements.</p>
<h3 id="correction">Correction</h3>
<p>Mild to moderate hypokalaemia may be treated with oral potassium supplements i.e Slow K at 1200 mg (16 mmol) BD or 10% of Potassium chloride solution given at 15 mls (20 mmol) 2-3 times daily. This dosage can be increased as needed. Monitor potassium every 48 hours.</p>
<p>Severe hypokalaemia is corrected with IV potassium chloride in normal saline infusion .</p>
<p>For patients with potassium level &lt; 3.0 mmol/l give a total 60 – 80 mmol of Potassium chloride in 24 hours at 10 mmol/hr. Patients with potassium levels between 3.0 and 3.4 mmol/l and cannot take potassium enterally give 20 – 40 mmol/l intravenously and in infusion.</p>
<p>Avoid using dextrose containing fluid for infusion.</p>
<p>Monitor potassium levels every 2-6 hours.</p>
<h1 id="hyperkalaemia">Hyperkalaemia </h1>
<p>In children and adults, this is defined as potassium levels &gt; 5.5 mmol/l. Mild hyperkalaemia is 5.5-5.9 mmol/L, moderate is 6.0-6.4 mmol/L and severe is ≥ 6.5 mmol/l. Severe hyperkalaemia is also present when serum potassium &gt; 5.5mmol/L with ECG changes. Unless samples are haemolysed, all cases of hyperkalaemia should be treated immediately.</p>
<p>For infants aged 2 weeks to 3 months, hyperkalaemia is defined as K &gt; 5.7 mmol/l.</p>
<p>For neonates aged less than 2 weeks, hyperkalaemia is defined as K &gt; 6.0 mmol/l.</p>
<h2 id="causes-of-hyperkalaemia">Causes of hyperkalaemia</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Extracellular shift: metabolic acidosis, rhabdomyolysis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Medications: succinylcholine, beta blockers and digoxin</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Reduced excretion- potassium sparing diuretics,renal failure</p>
</div></li>
</ul>
<h3 id="causes-of-pseudohyperkalaemia">Causes of pseudohyperkalaemia: </h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Prolonged tourniquet time or repeated fist clenching</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Test tube haemolysis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Sample contamination with potassium EDTA (anticoagulant)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Delayed analysis (prolonged storage of blood)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Marked leucocytosis and thrombocytosis (measure plasma not serum concentration in these disease states)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Sample taken from a vein infused with IV fluids containing potassium (hospital setting)</p>
</div></li>
</ul>
<p>These should be avoided when taking and analyzing samples. It should be kept in mind when reviewing laboratory results where there is high potassium level.</p>
<h2 id="presenting-symptoms-and-signs-1">Presenting symptoms and signs</h2>
<p>Patients are usually asymptomatic.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Muscle twitching</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Cramps</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Weakness and paralysis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>ECG changes: Peaked T waves, widened QRS complexes, Prolonged PR interval and prolonged QT interval</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Arrhythmias</p>
</div></li>
</ul>
<p>Note that the absence of ECG changes does not exclude severe hyperkalaemia and does not mean that the patient cannot die suddenly of an arrhythmia.</p>
<h2 id="management-1">Management </h2>
<p>All patients with hyperkalaemia should have an ECG done. Ideally they should be monitored during correction with an ECG<strong>.</strong></p>
<p>Stop all supplements containing potassium and all potassium-containing IV fluids. Review drugs and consider stopping drugs which cause K retention.</p>
<p>For severe hyperkalaemia:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>IV 10 ml of 10% calcium gluconate in a central vein or slowly over 2-3 minutes</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>IV 50 ml of 50% dextrose +10 units of soluble insulin over 10 minutes. In diabetes mellitus, if the blood sugar is raised, insulin should be given without glucose.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Give nebulised salbutamol 10mg stat.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Repeat potassium levels every one hour. If insulin is used, monitor blood sugar hourly too.</p>
</div></li>
</ul>
<p>These measures all temporarily shift the serum potassium into the cells. To remove potassium from the patient’s system, consider if furosemide is an appropriate treatment.</p>
<p>If hyperkalaemia remains intractable, patient should be referred to the teaching hospital for dialysis.</p>
<p>For mild to moderate hyperkalaemia, restrict potassium in diet and review medications.</p>
<h1 id="hypomagnaesemia">Hypomagnaesemia</h1>
<p>This is defined as serum magnesium levels less than 0.7 mmol/L. It is said to be severe if &lt; 0.4 mmol/L.</p>
<h2 id="causes-1">Causes</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Malnutrition</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Pancreatitis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Diarrhoea</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Diuretics</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Sepsis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Trauma</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Burn</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Alcoholism</p>
</div></li>
</ul>
<h2 id="presenting-symptoms-and-signs-2">Presenting symptoms and signs</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Seizures</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Coma</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Weakness</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Cardiac arrythmias.</p>
</div></li>
</ul>
<h2 id="management-2">Management </h2>
<p>Mild to moderate hypomagnesaemia: IV Magnesium sulphate solution 2 g in 100 ml 0.9% saline over 2 hours.</p>
<p>Severe hypomagnesaemia: IV Magnesium sulphate solution 4 – 6 g in 250 mls of 0.9% saline over 4 hours (not exceeding 12 g per day).</p>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Hypokalaemia and hyperkalaemia can both be associated with sudden cardiac death and must be treated.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Follow the fluid instructions very carefully.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Make sure repeat tests are done on time and are reviewed by a doctor promptly.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>All patients given insulin must have hourly bedside blood sugar monitoring.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Seek senior support if you are at all concerned about the patient.</p>
</div></li>
</ul>
<h2 id="references">References</h2>
<p>Bartel B, Gau E. Fluid and Electrolyte Management. Critical Care Pharmacotherapeutics. Burlington, MA: Jones &amp; Bartlett Learning. 2012 Feb 8:125-50.</p>
<p>Hoorn EJ, Tuut MK, Hoorntje SJ, van Saase JL, Zietse R, Geers AB. Dutch guideline for the management of electrolyte disorders-2012 revision. Neth J Med. 2013 Apr 1;71(3):153-65.</p>
<p>Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. American Journal of Health-System Pharmacy. 2005 Aug 15;62(16):1663-82.</p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th><p>Name: Orighomisan Agboghoroma</p>
<p>Mariama Sonko</p></th>
<th>Date: 07 January 2019</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Karen Forrest</td>
<td>Date: 09 May 2019</td>
</tr>
<tr class="even">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td>31 May 2021</td>
</tr>
<tr class="even">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
